Transperineal bests transrectal prostate biopsy for cancer detection

  • Jiang CY & al.
  • Asian J Androl
  • 19 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Transperineal prostate biopsy (TPBx) is better than transrectal prostate biopsy (TRBx) for detecting clinically significant prostate cancer.
  • Exceptions are patients age ≥80 years, with PSA levels >20 ng/mL, or with lower prostate volume (PV).

Why this matters

  • Understanding the differences between approaches can help reduce repeat biopsies and overtreatment.

Study design

  • Researchers compared the detection rates of systematic 12-core TPBx vs TRBx, both guided by transrectal ultrasound, in patients with suspected prostate cancer (N=2962).
  • Funding: National Natural Science Foundation of China; Shanghai Municipal Health Bureau.

Key results

  • TPBx detected clinically significant prostate cancer in a higher proportion of patients overall (P<.001>
  • TRBx detection rates were higher in patients who:
    • Were age ≥80 years: 80.4% vs 56.5% (P=.004).
    • Had PSA levels >20.1-100.0 ng/mL: 80.9% vs 69.1% (P=.040).
    • Had lower PV:
      • multivariable analysis OR, 0.982 (95% CI, 0.973-0.991; P<.001>
      • univariable analysis OR, 0.990 (95% CI, 0.983-0.997; P=.004).

Limitations

  • The study was retrospective and limited to patient data from 2 Chinese hospitals.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit